Welcome to our dedicated page for Lifestance Health Group SEC filings (Ticker: LFST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for LifeStance Health Group, Inc. (Nasdaq: LFST), a mental healthcare company focused on outpatient services. As a public company with common stock registered on The Nasdaq Stock Market LLC, LifeStance files documents such as annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.
LifeStance’s filings offer detailed information about its business as one of the nation’s largest providers of virtual and in-person outpatient mental healthcare. In these documents, the company describes its operations, risk factors, financial condition and results of operations. For example, current reports on Form 8-K have been used to furnish earnings press releases for specific quarters and to disclose changes in the board of directors, including director resignations and appointments with related equity awards under the company’s equity incentive plan.
Investors can review LifeStance’s discussion of non-GAAP financial measures such as Center Margin and Adjusted EBITDA, along with reconciliations to comparable GAAP measures, within its filings and related exhibits. The company also outlines forward-looking statements and associated risks, referring readers to the "Risk Factors" section of its Form 10-K and subsequent filings for more comprehensive risk disclosures.
On Stock Titan, LifeStance filings are updated as new documents are made available through the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy filings, highlight significant changes from prior periods and clarify technical language. Users can quickly identify items related to quarterly and annual results, governance events reported on Form 8-K and other regulatory disclosures relevant to LFST, while still having access to the full original documents for detailed review.
LifeStance Health Group, Inc. reported insider equity activity by its Chief Executive Officer, David Bourdon. On March 5, 2026, he acquired 395,683 shares of common stock through a grant of restricted stock units, with each RSU representing the right to receive one common share.
On March 6, 2026, 65,837 shares of common stock were withheld by the company at a price of $6.93 per share to cover tax obligations from vested RSUs. The footnote explains this was a tax-withholding disposition and did not involve any open-market sale of shares.
LifeStance Health Group director Kenneth A. Burdick reported a tax-related share withholding tied to vested restricted stock units. On March 6, 2026, the issuer withheld 424,551 shares of common stock at $7.11 per share to cover tax obligations, which the filing states is not an open-market sale. After this net settlement, Burdick directly holds 3,012,020 shares and indirectly holds 46,511 shares through Burdick Family LLC.
Paunovich Vukasin reported acquisition or exercise transactions in this Form 4 filing.
LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich was granted 86,331 shares of common stock in the form of restricted stock units (RSUs) on March 5, 2026. Each RSU represents a right to receive one share of common stock, increasing his directly held stake to 264,902 shares after the award.
LifeStance Health Group, Inc. reported that officer Lisa K. Miller received an equity grant of 107,914 restricted stock units on March 5, 2026. Each RSU represents a contingent right to receive one share of common stock.
On March 6, 2026, 21,590 shares of common stock were withheld by the company at $6.93 per share to cover tax obligations related to vested RSUs. The footnote states this was not an open-market sale but a reduction in shares issued upon settlement. After these transactions, Miller directly held 330,577 shares of common stock.
LifeStance Health Group, Inc. Chief People Officer Ann Varanakis reported two equity transactions in company common stock. On March 5, 2026, she acquired 86,331 restricted stock units as a grant, each representing a contingent right to receive one share of common stock.
On March 6, 2026, 21,566 shares were withheld by the company at a price of $6.93 per share to cover tax obligations upon settlement of vested RSUs. The footnote states this withholding reduced shares delivered to her and did not involve any open‑market sale.
LifeStance Health Group executive Ryan McGroarty reported an equity award of company stock. On March 5, 2026, he acquired 179,856 shares of common stock through a grant at a price of $0.00 per share, described as restricted stock units where each unit represents one share of common stock. Following this award, his directly held common stock holdings increased to 727,611 shares, including the newly granted RSUs, which vest into actual shares subject to their terms.
LifeStance Health Group, Inc. reported a large insider-related transaction involving entities affiliated with TPG. On March 2, 2026, an entity indirectly associated with the reporting persons completed an open-market sale of 20,685,061 shares of common stock at $7.01 per share. Following this sale, 140,026,557 shares of LifeStance common stock were reported as indirectly owned. According to the disclosures, the shares are directly held by TPG VIII Lynnwood Holdings Aggregation, L.P., and the reporting persons may be deemed to beneficially own the securities only to the extent of their respective pecuniary interests, which they expressly disclaim beyond that.
Entities affiliated with Summit Partners and associated with LifeStance Health Group director Darren M. Black sold 4,314,939 shares of LifeStance common stock in an open-market transaction at $7.01 per share. After these sales, the Summit-managed funds collectively held 29,209,776 LifeStance shares.
LifeStance Health Group, Inc. entered into an underwriting agreement with J.P. Morgan Securities LLC and certain selling stockholders for an underwritten public offering of 25,000,000 shares of its common stock under an effective Form S-3 shelf registration. All 25,000,000 shares are being sold by the selling stockholders, so the company did not receive any proceeds from this offering.
Under the same agreement, LifeStance agreed to repurchase 7,000,000 of these shares from the underwriter at the same price per share paid to the selling stockholders, and the underwriter received no compensation on the repurchased shares. The offering closed on March 2, 2026, and Ropes & Gray LLP provided a legal opinion on the shares, filed as an exhibit.
LifeStance Health Group, Inc. is registering 25,000,000 shares of its common stock for resale by selling stockholders under a prospectus supplement.
The offering is a resale by selling stockholders; the Company will receive no proceeds from these sales and intends, subject to the offering closing, to repurchase 7,000,000 shares at the underwriter purchase price and retire those repurchased shares. Shares outstanding used for disclosure were 389,783,210 shares as of February 17, 2026. The underwriter agreed to purchase the shares from the selling stockholders at $7.01 per share, and delivery is expected on or about March 2, 2026.